Carregant...

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models()

BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibitor crizotinib has proven to be effective in the treatment of ALK-mutated neuroblastoma, but crizotinib resistance was commonly observed in patients. We aimed to overcome crizotinib resistance by combining with the MEK inhibitor trametinib or low-do...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Oncol
Autors principals: Zhang, Libo, Wu, Bing, Baruchel, Sylvain
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5491461/
https://ncbi.nlm.nih.gov/pubmed/28666189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2017.04.008
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!